News
News
Academy
Multimedia
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in Medicine
Conferences
Conference CoverageConference Listing
More
Publications
Pharmaceutical Executive
Partner Perspectives
Resources
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers

Subscribe

  • News
  • Academy
  • Multimedia
  • Conferences
  • Publications
  • Partner Perspectives
  • Resources
  • Subscribe
  • Corporate Communications
    • Press Releases
    • Executive Roundtable
    • Executive Profiles
    • Leadership
  • Direct-to-Consumer
    • Patient Education
    • Healthcare Access
    • Telehealth
  • Emerging Biopharma
    • Partnerships
    • Funding
  • IR Licensing and Partnerships
    • Finance
    • Industry Trends
  • Market Access
    • Patient Access
    • Pricing
    • Strategy
  • Medical Affairs
    • Patient Advocacy
    • Clinical Data
    • Pharmacovigilance
  • Operations
    • Sustainability
    • Technology
    • R&D/Clinical Trials
    • Supply Chain
  • Patient Engagement
    • DE&I
  • Regulatory
    • FDA
    • Legal
    • Global
  • Sales & Marketing
    • Sales Effectiveness
    • Campaigns
    • DTC Marketing
    • Medical Education
Spotlight -
Latest Executive Roundtables|
Asembia 2025 |
Sales Effectiveness
Advertisement

Jennifer Juergens

Advertisement

Articles by Jennifer Juergens

i4-162154-1408695984989.gif

Recognize Reward Retain: The Three Rs of Performance Management

ByJennifer Juergens
May 1st 2005

Employees are most attracted to products they might feel guilty about buying for themselves, but when they have points to redeem, they feel fine about splurging.

Advertisement

Latest Updated Articles

  • i4-162154-1408695984989.gif
    Recognize Reward Retain: The Three Rs of Performance Management

    Published: May 1st 2005 | Updated:



Advertisement
Advertisement

Trending on PharmExec

1

Lilly’s Orforglipron, Retatrutide Named as Defining GLP-1 Drugs of the Next Decade

2

Johnson & Johnson Reaches Agreement with Trump Administration, Continues $55 Billion US-Based Investment Plan

3

Roundup: Pharma’s Funding Surge Ahead of J.P. Morgan 2026

4

Eli Lilly Enters $1.2 Billion Definitive Agreement to Acquire Ventyx Biosciences

5

FDA Limits Regulations on Non-Medical Grade Wearable Fitness Devices

  • About
  • Advertise
  • Contact Us
  • Editorial Board
  • Editorial Submission Guidelines
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us